The European Commission has published strategy on COVID-19 therapeutics to support the development and availability of medicines to treat the effects of the virus, covering the lifecycle of medicines from research, development and manufacturing, through to procurement and deployment. The strategy includes clear actions and targets, including authorising three new therapeutics to treat COVID-19 by October 2021 and possibly two more by end of the year. These actions and targets and grouped under the following headings:
-
Research, development and innovation
-
Access to, and swift approval of, clinical trials
-
Scanning for candidate therapeutics
-
Supply chains and delivery of medicines
-
Regulatory flexibility
-
Joint procurement and financing
-
International cooperation to make medicines available to all.
The Commission will draw up a portfolio of 10 potential COVID-19 therapeutics and by June 2021, identify the five most promising ones. In addition, it will organise events for industrial actors involved in therapeutics to ensure enough production capacity and swift manufacturing.
You can read more at: ://ec.europa.eu/commission/presscorner/detail/en/IP_21_2201
